Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jorge Castillo, M.D.

Title
Institution
Department
Address
Profile Picture

Biography
2012 - 2012
Best Lymphoma Abstract, Lymphoma & Myeloma 2012
1996 - 1996
Top 10%, UAM-X Medical School

Overview
Dr. Castillo was born in the northern coast of Peru. He received his medical degree in Mexico City, and completed his Hematology and Oncology training at Brown University. After 5 years as an Assistant Professor of Medicine at Brown University, Dr. Castillo was appointed Assistant Professor at Harvard Medical School. His clinical practice and research interests at the Dana-Farber Cancer Institute focus on patients with Waldenstrom Macroglobulinemia. He is currently the principal investigator in a series of clinical trials evaluating highly effective non-chemotherapeutic approaches.

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Jurczyszyn A, Waszczuk-Gajda A, Castillo JJ, Krawczyk K, Stork M, Pour L, Usnarska-Zubkiewicz L, Potoczek S, Hus I, Davila Valls J, Hari P, Chhabra S, Gentile M, Mikala G, Varga G, Chim CS, Fiala M, Vij R, Schutz N, Rodzaj M, Porowska A, Vesole DH, Druzd-Sitek A, Walewski J, Nooka AK. Primary refractory multiple myeloma: a real-world experience with 85 cases. Leuk Lymphoma. 2020 Jul 05; 1-8. PMID: 32623944.
    Citations:    
  2. Aguilar C, Laberiano C, Beltran B, Diaz C, Taype-Rondan A, Castillo JJ. Clinicopathologic characteristics and survival of patients with primary effusion lymphoma. Leuk Lymphoma. 2020 May 25; 1-10. PMID: 32449626.
    Citations:    
  3. Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K, Yang G. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915. PMID: 32302379.
    Citations:    
  4. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. Hemasphere. 2020 Jun; 4(3):e363. PMID: 32647793.
    Citations:    
  5. Beltrán BE, Villela L, Torres MA, Otero V, Fiad L, Peña C, Cabrera ME, León P, Idrobo H, Castro DA, Paredes S, Perdomo I, Abello V, Rojas C, Ramirez-Ibargüen A, Candelaria M, Pérez-Jacobo F, Montaño-Figueroa E, Best C, Goméz-De Leon A, Gómez-Almaguer D, Ruiz-Argüelles G, Hernández-Hernández J, Malpica L, Sotomayor EM, Castillo JJ. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Patients With Diffuse Large B-Cell Lymphoma: A Study From The Latin American Group of Lymphoproliferative Disorders (GELL). Clin Lymphoma Myeloma Leuk. 2020 May 04. PMID: 32513598.
    Citations:    
  6. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grzasko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Valls JD, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski L, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Mazur P, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozlowska I, Goldberg SL, Czepiel J, Dlugosz-Danecka M, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Vesole DH. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. Leuk Lymphoma. 2020 Apr 19; 1-9. PMID: 32306794.
    Citations:    
  7. Goldman-Mazur S, Jurczyszyn A, Castillo JJ, Waszczuk-Gajda A, Grzasko N, Radocha J, Bittrich M, Kortüm KM, Gozzetti A, Usnarska-Zubkiewicz L, Davila Valls J, Jayabalan DS, Niesvizky R, Kelman J, Coriu D, Rosiñol L, Szukalski L, González-Calle V, Mateos MV, Jamroziak K, Hus I, Avivi I, Cohen Y, Suska A, Chappell A, Madduri D, Chhabra S, Kleman A, Hari P, Delforge M, Robak P, Gentile M, Kozlowska I, Goldberg SL, Czepiel J, Silbermann R, Olszewski AJ, Barth P, Mikala G, Chim CS, Dlugosz-Danecka M, Grosicki S, Vesole DH. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. Am J Hematol. 2020 05; 95(5):503-509. PMID: 32072687.
    Citations:    
  8. Jiménez C, Chan GG, Xu L, Tsakmaklis N, Kofides A, Demos MG, Chen J, Liu X, Munshi M, Yang G, Castillo JJ, Wiestner A, García-Sanz R, Treon SP, Hunter ZR. Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia. Br J Haematol. 2020 Jun; 189(6):1165-1170. PMID: 32103491.
    Citations:    
  9. Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X, Demos M, Gustine J, Chan G, Munshi M, Tsakmaklis N, Chen JG, Kofides A, Sklavenitis-Pistofidis R, Bustoros M, Keezer A, Meid K, Patterson CJ, Sacco A, Roccaro A, Branagan AR, Yang G, Ghobrial IM, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol. 2020 Apr 10; 38(11):1198-1208. PMID: 32083995.
    Citations:    
  10. Beltran BE, Castro D, Paredes S, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020 Feb 18. PMID: 32072672.
    Citations:    
  11. Munshi M, Liu X, Chen JG, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Jimenez C, Chan GG, Hunter ZR, Palomba ML, Argyropoulos KV, Meid K, Keezer A, Gustine J, Dubeau T, Castillo JJ, Patterson CJ, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer J. 2020 01 31; 10(1):12. PMID: 32005797.
    Citations:    
  12. Castillo JJ, Itchaki G, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. Leuk Lymphoma. 2020 Jun; 61(6):1388-1394. PMID: 31992103.
    Citations:    
  13. Liu X, Chen JG, Munshi M, Hunter ZR, Xu L, Kofides A, Tsakmaklis N, Demos MG, Guerrera ML, Chan GG, Jimenez C, Patterson CJ, Meid K, Keezer A, Castillo JJ, Treon SP, Yang G. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. Blood Adv. 2020 Jan 14; 4(1):141-153. PMID: 31935288.
    Citations:    
  14. Castillo JJ, Gustine JN, Meid K, Flynn CA, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. CXCR4 mutational status does not impact outcomes in patients with Waldenström macroglobulinemia treated with proteasome inhibitors. Am J Hematol. 2020 Jan 13. PMID: 31943341.
    Citations:    
  15. Castillo JJ, Gustine JN, Keezer A, Meid K, Flynn CA, Dubeau TE, Chan G, Chen J, Demos MG, Guerrera ML, Jimenez C, Kofides A, Liu X, Munshi M, Tsakmaklis N, Patterson CJ, Xu L, Yang G, Hunter ZR, Treon SP. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. Am J Hematol. 2019 Dec 23. PMID: 31868242.
    Citations:    
  16. Olszewski AJ, Butera JN, Reagan JL, Castillo JJ. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2019 Dec 17. PMID: 31849108.
    Citations:    
  17. Castillo JJ. Evolution of Therapy for Relapsed/Refractory Multiple Myeloma. J Natl Compr Canc Netw. 2019 11; 17(11.5):1433-1436. PMID: 31766022.
    Citations:    
  18. Gustine JN, Xu L, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Keezer A, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ. CXCR4S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. Blood Adv. 2019 10 08; 3(19):2800-2803. PMID: 31570491.
    Citations:    
  19. Castillo JJ, Treon SP. What is new in the treatment of Waldenstrom macroglobulinemia? Leukemia. 2019 11; 33(11):2555-2562. PMID: 31591468.
    Citations:    
  20. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. J Natl Compr Canc Netw. 2019 10 01; 17(10):1154-1165. PMID: 31590151.
    Citations:    
  21. Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019 11; 187(3):277-285. PMID: 31430829.
    Citations:    
  22. Bustoros M, Sklavenitis-Pistofidis R, Castillo JJ, Treon SP, Ghobrial IM. Reply to F.D. Leonard. J Clin Oncol. 2019 10 10; 37(29):2701-2702. PMID: 31424980.
    Citations:    
  23. Avivi I, Cohen YC, Suska A, Shragai T, Mikala G, Garderet L, Seny GM, Glickman S, Jayabalan DS, Niesvizky R, Gozzetti A, Wisniewska-Piaty K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Hus I, Guzicka R, Radocha J, Milunovic V, Davila J, Gentile M, Castillo JJ, Jurczyszyn A. Hematogenous extramedullary relapse in multiple myeloma - a multicenter retrospective study in 127 patients. Am J Hematol. 2019 10; 94(10):1132-1140. PMID: 31334859.
    Citations:    
  24. Castillo JJ. HOLA! from Latin America to the myeloma world. Br J Haematol. 2020 02; 188(3):349-350. PMID: 31378927.
    Citations:    
  25. Castillo JJ, Moreno DF, Arbelaez MI, Hunter ZR, Treon SP. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review. Expert Rev Hematol. 2019 10; 12(10):873-881. PMID: 31343930.
    Citations:    
  26. Castillo JJ, Xu L, Gustine JN, Keezer A, Meid K, Dubeau TE, Liu X, Demos MG, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Yang G, Hunter ZR, Treon SP. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019 11; 187(3):356-363. PMID: 31267520.
    Citations:    
  27. Beltran BE, Paredes S, Castro D, Cotrina E, Sotomayor EM, Castillo JJ. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy. Clin Lymphoma Myeloma Leuk. 2019 09; 19(9):e551-e557. PMID: 31320254.
    Citations:    
  28. Juárez-Salcedo LM, Castillo JJ. Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. Hematol Oncol Clin North Am. 2019 08; 33(4):639-656. PMID: 31229160.
    Citations:    
  29. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, Dimopoulos MA, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. PMID: 30990729.
    Citations:    
  30. Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019 01 24; 133(4):299-305. PMID: 30523119.
    Citations:    Fields:    
  31. Cheng MP, Kusztos AE, Gustine JN, Dryden-Peterson SL, Dubeau TE, Woolley AE, Hammond SP, Baden LR, Treon SP, Castillo JJ, Issa NC. Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib. Br J Haematol. 2019 05; 185(4):788-790. PMID: 30460682.
    Citations:    Fields:    
  32. Barth P, Castillo JJ, Olszewski AJ. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019 02 15; 125(4):550-558. PMID: 30452087.
    Citations:    Fields:    
  33. Olszewski AJ, Castillo JJ. Ibrutinib and Rituximab in Waldenström's Macroglobulinemia. N Engl J Med. 2018 11 15; 379(20):1973-4. PMID: 30439672.
    Citations:    Fields:    Translation:Humans
  34. Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946. PMID: 30401751.
    Citations:    
  35. Babwah A, Gustine J, Meid K, Dubeau T, Xu L, Yang G, Hunter ZR, Treon SP, Castillo JJ. Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. Br J Haematol. 2019 05; 185(4):799-802. PMID: 30407630.
    Citations:    Fields:    
  36. Sklavenitis-Pistofidis R, Capelletti M, Liu CJ, Reidy M, Zavidij O, Huynh D, Henrick P, Savell A, Reyes K, Rivotto B, Bustoros M, Perilla-Glen A, Trippa L, Castillo JJ, Treon SP, Ghobrial IM. Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood. 2018 12 13; 132(24):2608-2612. PMID: 30366921.
    Citations:    Fields:    
  37. Bouyssou JM, Liu CJ, Bustoros M, Sklavenitis-Pistofidis R, Aljawai Y, Manier S, Yosef A, Sacco A, Kokubun K, Tsukamoto S, Perilla Glen A, Huynh D, Castillo JJ, Treon SP, Leblond V, Hermine O, Roccaro AM, Ghobrial IM, Capelletti M. Profiling of circulating exosomal miRNAs in patients with Waldenström Macroglobulinemia. PLoS One. 2018; 13(10):e0204589. PMID: 30286096.
    Citations:    Fields:    
  38. Castillo JJ, Kastritis E, Treon SP. Waldenström Macroglobulinemia: Lessons Learned from Basic and Clinical Research. Hematol Oncol Clin North Am. 2018 10; 32(5):xiii-xiv. PMID: 30190026.
    Citations:    Fields:    
  39. Gustine JN, Tsakmaklis N, Demos MG, Kofides A, Chen JG, Liu X, Munshi M, Guerrera ML, Chan GG, Patterson CJ, Meid K, Dubeau T, Yang G, Hunter ZR, Treon SP, Castillo JJ, Xu L. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia. Br J Haematol. 2019 01; 184(2):242-245. PMID: 30183082.
    Citations: 1     Fields:    
  40. Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA. Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. Am J Hematol. 2018 09; 93(9):E238-E241. PMID: 29989240.
    Citations:    Fields:    
  41. Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2018 09 20; 36(27):2755-2761. PMID: 30044692.
    Citations: 1     Fields:    
  42. Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ. Genomic Landscape of Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):745-752. PMID: 30190014.
    Citations:    Fields:    
  43. Castillo JJ, Treon SP. Initial Evaluation of the Patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 10; 32(5):811-820. PMID: 30190019.
    Citations:    Fields:    
  44. Jurczyszyn A, Davila J, Kortüm KM, Jayabalan DS, Vij R, Fiala M, Milunovic V, Chim CS, Wisniewska-Piaty K, Waszczuk-Gajda A, Crusoe E, Hajek R, Robak P, Razny M, Zawirska D, Bittrich M, Nahi H, Liu J, Castillo JJ, Vesole DH. Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. Leuk Lymphoma. 2019 02; 60(2):471-476. PMID: 30033832.
    Citations:    Fields:    
  45. Dominguez A, Kastritis E, Castillo JJ. Monoclonal Antibodies for Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct; 32(5):841-852. PMID: 30190022.
    Citations:    Fields:    
  46. Jurczyszyn A, Castillo JJ, Avivi I, Czepiel J, Davila J, Vij R, Fiala MA, Gozzetti A, Grzasko N, Milunovic V, Hus I, Madry K, Waszczuk-Gajda A, Usnarska-Zubkiewicz L, Debski J, Atilla E, Beksac M, Mele G, Sawicki W, Jayabalan D, Charlinski G, Gyula Szabo A, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Crusoe E, Hungria V, Richardson P, Laubach J, Guerrero-Garcia T, Liu J, Vesole DH. Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. Leuk Lymphoma. 2019 01; 60(1):118-123. PMID: 29965787.
    Citations:    Fields:    
  47. Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2018 update on diagnosis, risk-stratification and management. Am J Hematol. 2018 07; 93(7):953-962. PMID: 29984868.
    Citations:    Fields:    
  48. Treon SP, Castillo JJ. The real world of Waldenström's macroglobulinaemia. Lancet Haematol. 2018 07; 5(7):e275-e276. PMID: 29958567.
    Citations:    Fields:    Translation:Humans
  49. Castillo JJ. Viral lymphomagenesis: beyond the usual suspects. Br J Haematol. 2018 09; 182(5):617-618. PMID: 29808932.
    Citations:    Fields:    
  50. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Xu L, Yang G, Hunter ZR, Advani R, Palomba L, Treon SP. Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia. Haematologica. 2018 10; 103(10):e466-e468. PMID: 29773590.
    Citations:    Fields:    
  51. Castillo JJ, Dubeau T, Kofides A, Demos MG, Tsakmaklis N, Xu L, Hunter ZR, Treon SP. Spotting the elusive Siberian tiger: Complete response to ibrutinib in a patient with Waldenström Macroglobulinemia. Am J Hematol. 2018 May 14. PMID: 29756293.
    Citations:    Fields:    
  52. Castillo JJ, Gustine JN, Treon SP. Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia. JAMA Oncol. 2018 05 01; 4(5):744-745. PMID: 29392274.
    Citations:    Fields:    
  53. Singh A, Geller HI, Alexander KM, Padera RF, Mitchell RN, Dorbala S, Castillo JJ, Falk RH. True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. Haematologica. 2018 08; 103(8):e374-e376. PMID: 29674499.
    Citations:    Fields:    
  54. Castillo JJ, Meid K, Gustine JN, Dubeau T, Severns P, Hunter ZR, Yang G, Xu L, Treon SP. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. Clin Cancer Res. 2018 07 15; 24(14):3247-3252. PMID: 29661775.
    Citations:    Fields:    
  55. Guerrera ML, Tsakmaklis N, Xu L, Yang G, Demos M, Kofides A, Chan GG, Manning RJ, Liu X, Chen JG, Munshi M, Patterson CJ, Castillo JJ, Dubeau T, Gustine J, Carrasco RD, Arcaini L, Varettoni M, Cazzola M, Treon SP, Hunter ZR. MYD88 mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica. 2018 09; 103(9):e408-e411. PMID: 29599202.
    Citations: 1     Fields:    
  56. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 03; 184(6):1011-1014. PMID: 29532913.
    Citations:    Fields:    
  57. Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019 02; 184(4):679-682. PMID: 29527667.
    Citations:    Fields:    
  58. Chen JG, Liu X, Munshi M, Xu L, Tsakmaklis N, Demos MG, Kofides A, Guerrera ML, Chan GG, Patterson CJ, Meid K, Gustine J, Dubeau T, Severns P, Castillo JJ, Hunter ZR, Wang J, Buhrlage SJ, Gray NS, Treon SP, Yang G. BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism. Blood. 2018 05 03; 131(18):2047-2059. PMID: 29496671.
    Citations: 2     Fields:    
  59. Beltran BE, Castro D, De La Cruz-Vargas JA, Cotrina E, Gallo A, Sotomayor EM, Castillo JJ. The neutrophil-lymphocyte ratio is prognostic in patients with early stage aggressive peripheral T cell lymphoma. Br J Haematol. 2019 02; 184(4):650-653. PMID: 29479670.
    Citations:    Fields:    
  60. Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018 04; 181(1):77-85. PMID: 29468652.
    Citations: 1     Fields:    
  61. Castillo JJ, Gustine JN, Meid K, Dubeau T, Severns P, Treon SP. Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. Haematologica. 2018 07; 103(7):e307-e310. PMID: 29472352.
    Citations:    Fields:    
  62. Beltrán BE, Paredes S, Cotrina E, Sotomayor EM, Castillo JJ. The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85. PMID: 29477024.
    Citations:    Fields:    
  63. Gustine JN, Meid K, Dubeau T, Severns P, Hunter ZR, Guang Y, Xu L, Treon SP, Castillo JJ. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. Am J Hematol. 2018 08; 93(4):511-517. PMID: 29280186.
    Citations: 2     Fields:    
  64. Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grzasko N, Robak P, Hus I, Waszczuk-Gajda A, Guzicka-Kazimierczak R, Atilla E, Mele G, Sawicki W, Jayabalan DS, Charlinski G, Szabo AG, Hajek R, Delforge M, Kopacz A, Fantl D, Waage A, Avivi I, Rodzaj M, Leleu X, Richez V, Knopinska-Posluszny W, Masternak A, Yee AJ, Barchnicka A, Druzd-Sitek A, Guerrero-Garcia T, Liu J, Vesole DH, Castillo JJ. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018 03; 180(6):831-839. PMID: 29315478.
    Citations:    Fields:    
  65. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin T, Neppalli VT, Omel J, Raje N, Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shead DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018 01; 16(1):11-20. PMID: 29295877.
    Citations: 1     Fields:    
  66. Castillo JJ, Gustine JN, Meid K, Xu L, Hunter ZR, Treon SP. Comparing apples to oranges: A commentary on the Mayo study of MYD88 significance in Waldenstrom's macroglobulinemia. Am J Hematol. 2018 03; 93(3):E69-E71. PMID: 29218718.
    Citations:    Fields:    
  67. Castillo JJ, Treon SP. Toward personalized treatment in Waldenström macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):365-370. PMID: 29222280.
    Citations:    Fields:    Translation:Humans
  68. Treon SP, Castillo JJ. What should be the goal of therapy for Waldenström macroglobulinemia patients? Complete response should be the goal of therapy. Blood Adv. 2017 Nov 28; 1(25):2486-2490. PMID: 29296899.
    Citations:    
  69. Treon SP, Gustine J, Xu L, Manning RJ, Tsakmaklis N, Demos M, Meid K, Guerrera ML, Munshi M, Chan G, Chen J, Kofides A, Patterson CJ, Yang G, Liu X, Severns P, Dubeau T, Hunter ZR, Castillo JJ. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 02; 180(3):374-380. PMID: 29181840.
    Citations: 3     Fields:    Translation:Humans
  70. Beltran BE, Quiñones P, Sanchez G, Paredes A, Moises C, Cotrina E, Torres-Cabala CA, Miranda RN, Castillo JJ. Primary cutaneous plasmablastic lymphoma in an immunocompetent patient: is it associated with an indolent course? Leuk Lymphoma. 2018 07; 59(7):1753-1755. PMID: 29081245.
    Citations:    Fields:    Translation:Humans
  71. Olszewski AJ, Reagan JL, Castillo JJ. Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas. Am J Hematol. 2018 01; 93(1):E1-E3. PMID: 28960532.
    Citations:    Fields:    Translation:Humans
  72. Qunaj L, Castillo JJ, Olszewski AJ. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma. 2018 06; 59(6):1375-1383. PMID: 29019447.
    Citations:    Fields:    Translation:HumansPHPublic Health
  73. Guerrero-Garcia TA, Mogollon RJ, Castillo JJ. Bortezomib in plasmablastic lymphoma: A glimpse of hope for a hard-to-treat disease. Leuk Res. 2017 11; 62:12-16. PMID: 28963907.
    Citations: 3     Fields:    Translation:Humans
  74. Vos JM, Tsakmaklis N, Patterson CJ, Meid K, Castillo JJ, Brodsky P, Ganz T, Pals ST, Kersten MJ, Xu L, Yang G, Treon SP, Hunter ZR. CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. Haematologica. 2017 11; 102(11):e452-e455. PMID: 28798070.
    Citations: 1     Fields:    Translation:Humans
  75. Jurczyszyn A, Gozzetti A, Gdula-Argasinska J, Czepiel J, Vij R, Fiala M, Valls DJ, Madry K, Waszczuk-Gajda A, Grosicki S, Barchnicka A, Crusoe E, Hungria V, Gentile M, Mele G, Ksieniewicz M, Vesole DH, Castillo JJ. Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. Ann Hematol. 2017 Oct; 96(10):1693-1698. PMID: 28766002.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  76. Olszewski AJ, Chen C, Gutman R, Treon SP, Castillo JJ. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia. Br J Haematol. 2017 10; 179(1):106-115. PMID: 28677830.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  77. Castillo JJ, Hunter ZR, Yang G, Treon SP. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia. Expert Rev Hematol. 2017 08; 10(8):739-744. PMID: 28617062.
    Citations:    Fields:    Translation:HumansAnimalsCells
  78. Beltran BE, Quiñones P, Morales D, Malaga JM, Chavez JC, Sotomayor EM, Castillo JJ. Response and survival benefit with chemoimmunotherapy in Epstein-Barr virus-positive diffuse large B-cell lymphoma. Hematol Oncol. 2018 Feb; 36(1):93-97. PMID: 28639256.
    Citations: 1     Fields:    Translation:Humans
  79. Castillo JJ, Jurczyszyn A, Brozova L, Crusoe E, Czepiel J, Davila J, Dispenzieri A, Eveillard M, Fiala MA, Ghobrial IM, Gozzetti A, Gustine JN, Hajek R, Hungria V, Jarkovsky J, Jayabalan D, Laubach JP, Lewicka B, Maisnar V, Manasanch EE, Moreau P, Morgan EA, Nahi H, Niesvizky R, Paba-Prada C, Pika T, Pour L, Reagan JL, Richardson PG, Shah J, Spicka I, Vij R, Waszczuk-Gajda A, Gertz MA. IgM myeloma: A multicenter retrospective study of 134 patients. Am J Hematol. 2017 Aug; 92(8):746-751. PMID: 28383205.
    Citations: 1     Fields:    Translation:HumansCells
  80. Gustine JN, Meid K, Dubeau T, Hunter ZR, Xu L, Yang G, Ghobrial IM, Treon SP, Castillo JJ. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017 06; 177(5):717-725. PMID: 28485115.
    Citations: 3     Fields:    Translation:Humans
  81. Xu L, Tsakmaklis N, Yang G, Chen JG, Liu X, Demos M, Kofides A, Patterson CJ, Meid K, Gustine J, Dubeau T, Palomba ML, Advani R, Castillo JJ, Furman RR, Hunter ZR, Treon SP. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia. Blood. 2017 05 04; 129(18):2519-2525. PMID: 28235842.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  82. D'Sa S, Kersten MJ, Castillo JJ, Dimopoulos M, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017 03; 176(5):728-742. PMID: 28198999.
    Citations: 6     Fields:    Translation:Humans
  83. Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. J Clin Oncol. 2017 Mar 20; 35(9):994-1001. PMID: 28294689.
    Citations: 6     Fields:    Translation:HumansCells
  84. Dimopoulos MA, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, García-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsonis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb; 18(2):241-250. PMID: 27956157.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  85. Treon SP, Meid K, Tripsas C, Heffner LT, Eradat H, Badros AZ, Xu L, Hunter ZR, Yang G, Patterson CJ, Gustine J, Castillo JJ, Matous J, Ghobrial IM. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15; 23(10):2400-2404. PMID: 27836860.
    Citations: 1     Fields:    Translation:HumansCellsCTClinical Trials
  86. Gustine JN, Meid K, Hunter ZR, Xu L, Treon SP, Castillo JJ. MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinaemia. Br J Haematol. 2018 02; 180(4):578-581. PMID: 27748515.
    Citations: 3     Fields:    Translation:Humans
  87. Castillo JJ. Plasma Cell Disorders. Prim Care. 2016 Dec; 43(4):677-691. PMID: 27866585.
    Citations:    Fields:    Translation:HumansCells
  88. Minnema MC, Kimby E, D'Sa S, Fornecker LM, Poulain S, Snijders TJ, Kastritis E, Kremer S, Fitsiori A, Simon L, Davi F, Lunn M, Castillo JJ, Patterson CJ, Le Garff-Tavernier M, Costopoulos M, Leblond V, Kersten MJ, Dimopoulos MA, Treon SP. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica. 2017 01; 102(1):43-51. PMID: 27758817.
    Citations: 6     Fields:    Translation:Humans
  89. Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT, Rasche L, Madry K, Woszczyk D, Razny M, Usnarska-Zubkiewicz L, Knopinska-Posluszny W, Wojciechowska M, Guzicka-Kazimierczak R, Joks M, Grosicki S, Ciepluch H, Rymko M, Vesole DH, Castillo JJ. Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study. Br J Haematol. 2016 Dec; 175(5):884-891. PMID: 27682187.
    Citations:    Fields:    Translation:Humans
  90. Castillo JJ, Hunter ZR, Yang G, Argyropoulos K, Palomba ML, Treon SP. Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol. 2016 06; 29(2):206-215. PMID: 27825467.
    Citations: 1     Fields:    Translation:Humans
  91. Olszewski AJ, Mantripragada KC, Castillo JJ. Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma. J Natl Compr Canc Netw. 2016 09; 14(9):1121-9. PMID: 27587624.
    Citations: 1     Fields:    Translation:Humans
  92. Castillo JJ. Risk factors for progression from smoldering into active myeloma: additional insights from a population-based study. Eur J Haematol. 2016 Sep; 97(3):217-8. PMID: 26918423.
    Citations:    Fields:    Translation:HumansPHPublic Health
  93. Castillo JJ, Gustine JN, Meid K, Dubeau T, Yang G, Xu L, Hunter ZR, Treon SP. Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004. PMID: 27562445.
    Citations: 4     Fields:    Translation:Humans
  94. Castillo JJ, Gertz MA. Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance. Leuk Lymphoma. 2017 04; 58(4):773-780. PMID: 27546465.
    Citations: 1     Fields:    Translation:Humans
  95. Castillo JJ, Glezerman IG, Boklage SH, Chiodo J, Tidwell BA, Lamerato LE, Schulman KL. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 2016 07 29; 16:564. PMID: 27473121.
    Citations: 4     Fields:    Translation:Humans
  96. Vos JM, Gustine J, Rennke HG, Hunter Z, Manning RJ, Dubeau TE, Meid K, Minnema MC, Kersten MJ, Treon SP, Castillo JJ. Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. Br J Haematol. 2016 Nov; 175(4):623-630. PMID: 27468978.
    Citations: 8     Fields:    Translation:Humans
  97. Olszewski AJ, Treon SP, Castillo JJ. Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. Oncologist. 2016 Nov; 21(11):1377-1386. PMID: 27473042.
    Citations: 4     Fields:    
  98. Levin SN, de Gusmao CM, Etherton MR, Will Rondeau M, Meredith DM, Folkerth RD, Klein JP, Nadeem O, Castillo JJ. "All the soarings of my mind begin in my blood:" central nervous system complication of Waldenström macroglobulinemia. Am J Hematol. 2016 Oct; 91(10):1057-60. PMID: 27414991.
    Citations:    Fields:    Translation:Humans
  99. Castillo JJ, Gustine J, Meid K, Dubeau T, Hunter ZR, Treon SP. Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. Am J Hematol. 2016 10; 91(10):1032-5. PMID: 27415417.
    Citations: 5     Fields:    Translation:Humans
  100. Leblond V, Kastritis E, Advani R, Ansell SM, Buske C, Castillo JJ, García-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, Dimopoulos MA. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 09 08; 128(10):1321-8. PMID: 27432877.
    Citations: 9     Fields:    Translation:Humans
  101. Mason C, Savona S, Rini JN, Castillo JJ, Xu L, Hunter ZR, Treon SP, Allen SL. Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome. Br J Haematol. 2017 10; 179(2):339-341. PMID: 27409073.
    Citations: 7     Fields:    Translation:Humans
  102. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, Dimopoulos MA, Treon SP, Kastritis E. Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. Br J Haematol. 2016 10; 175(1):77-86. PMID: 27378193.
    Citations: 6     Fields:    Translation:Humans
  103. Olszewski AJ, Fallah J, Castillo JJ. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 2016 09 01; 122(17):2689-97. PMID: 27337679.
    Citations: 6     Fields:    Translation:Humans
  104. Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X, Chen J, Manning RJ, Chen JG, Brodsky P, Patterson CJ, Gustine J, Dubeau T, Castillo JJ, Anderson KC, Munshi NM, Treon SP. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38. PMID: 27301862.
    Citations: 8     Fields:    Translation:HumansCells
  105. Castillo JJ, Palomba ML, Advani R, Treon SP. Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience. Ther Adv Hematol. 2016 Aug; 7(4):179-86. PMID: 27493708.
    Citations: 4     
  106. Yang G, Buhrlage SJ, Tan L, Liu X, Chen J, Xu L, Tsakmaklis N, Chen JG, Patterson CJ, Brown JR, Castillo JJ, Zhang W, Zhang X, Liu S, Cohen P, Hunter ZR, Gray N, Treon SP. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood. 2016 06 23; 127(25):3237-52. PMID: 27143257.
    Citations: 4     Fields:    Translation:HumansCells
  107. Marini C, Baldaia H, Trigo F, Castillo JJ. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol. 2016 Aug; 91(8):E324. PMID: 27012155.
    Citations:    Fields:    Translation:HumansCells
  108. Castillo JJ, Beltran BE, Miranda RN, Young KH, Chavez JC, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016 May; 91(5):529-37. PMID: 27093913.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  109. Gustine JN, Meid K, Dubeau TE, Treon SP, Castillo JJ. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia. Am J Hematol. 2016 06; 91(6):E312-3. PMID: 26994323.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  110. Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80. PMID: 26955792.
    Citations: 3     Fields:    Translation:Humans
  111. Liu X, Hunter ZR, Xu L, Chen J, Chen JG, Tsakmaklis N, Patterson CJ, Castillo JJ, Buhrlage S, Gray N, Treon SP, Yang G. Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia. Br J Haematol. 2017 06; 177(5):808-813. PMID: 27073043.
    Citations: 1     Fields:    Translation:HumansCells
  112. Castillo JJ, Ghobrial IM, Treon SP. Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leuk Lymphoma. 2016 11; 57(11):2699-701. PMID: 26980069.
    Citations: 1     Fields:    Translation:Humans
  113. Olszewski AJ, Castillo JJ. Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy. AIDS. 2016 Mar 13; 30(5):787-96. PMID: 26730566.
    Citations: 4     Fields:    Translation:Humans
  114. Gustine J, Meid K, Xu L, Hunter ZR, Castillo JJ, Treon SP. To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. Br J Haematol. 2017 03; 176(5):822-824. PMID: 26936399.
    Citations: 4     Fields:    Translation:HumansCells
  115. Castillo JJ, Grohé C, Verbalis JG. Cancer-Related Hyponatremia: Enhancing Recognition and Improving Management. Clin Lung Cancer. 2016 Mar; 17(2):e29. PMID: 26969388.
    Citations:    
  116. Roccaro AM, Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 05 26; 127(21):2598-606. PMID: 26903547.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  117. Olszewski AJ, Falah J, Castillo JJ. Survival Claims From Observational Data on Cancer Therapy. J Clin Oncol. 2016 Apr 20; 34(12):1425-7. PMID: 26884574.
    Citations: 1     Fields:    Translation:Humans
  118. Jurczyszyn A, Olszewska-Szopa M, Hungria V, Crusoe E, Pika T, Delforge M, Leleu X, Rasche L, Nooka AK, Druzd-Sitek A, Walewski J, Davila J, Caers J, Maisnar V, Gertz M, Gentile M, Fantl D, Mele G, Vesole DH, Yee AJ, Shustik C, Lentzsch S, Zweegman S, Gozzetti A, Skotnicki AB, Castillo JJ. Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. Leuk Lymphoma. 2016 09; 57(9):2071-6. PMID: 26726867.
    Citations: 3     Fields:    Translation:Humans
  119. Castillo JJ, Treon SP, Davids MS. Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. Cancer J. 2016 Jan-Feb; 22(1):34-9. PMID: 26841015.
    Citations: 5     Fields:    Translation:HumansCells
  120. Castillo JJ, D'Sa S, Lunn MP, Minnema MC, Tedeschi A, Lansigan F, Palomba ML, Varettoni M, Garcia-Sanz R, Nayak L, Lee EQ, Rinne ML, Norden AD, Ghobrial IM, Treon SP. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol. 2016 Mar; 172(5):709-15. PMID: 26686858.
    Citations: 8     Fields:    Translation:Humans
  121. Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44. PMID: 26659815.
    Citations: 13     Fields:    Translation:Humans
  122. Castillo JJ, Mulkey F, Geyer S, Kolitz JE, Blum W, Powell BL, George SL, Larson RA, Stone RM. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016 Feb; 91(2):199-204. PMID: 26526191.
    Citations: 2     Fields:    Translation:Humans
  123. Castillo JJ, Kanan S, Meid K, Manning R, Hunter ZR, Treon SP. Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol. 2016 08; 174(4):645-8. PMID: 26523929.
    Citations: 3     Fields:    Translation:Humans
  124. Sánchez-Guerrero S, Castillo JJ. Bing-Neel syndrome: a rare complication of Waldenström macroglobulinemia. Blood. 2015 Sep 10; 126(11):1390. PMID: 26605390.
    Citations: 1     Fields:    Translation:HumansCells
  125. Ghobrial IM, Redd R, Armand P, Banwait R, Boswell E, Chuma S, Huynh D, Sacco A, Roccaro AM, Perilla-Glen A, Noonan K, MacNabb M, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 2015 Dec; 29(12):2338-46. PMID: 26139427.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  126. Beltran BE, Aguilar C, Quiñones P, Morales D, Chavez JC, Sotomayor EM, Castillo JJ. The neutrophil-to-lymphocyte ratio is an independent prognostic factor in patients with peripheral T-cell lymphoma, unspecified. Leuk Lymphoma. 2016; 57(1):58-62. PMID: 25926063.
    Citations: 6     Fields:    Translation:HumansCells
  127. Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015 Aug; 26(8):1163-72. PMID: 26054914.
    Citations: 3     Fields:    Translation:Humans
  128. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database. Am J Hematol. 2015 Aug; 90(8):696-701. PMID: 25963924.
    Citations: 1     Fields:    Translation:Humans
  129. Leblebjian H, Noonan K, Paba-Prada C, Treon SP, Castillo JJ, Ghobrial IM. Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. Am J Hematol. 2015 Jun; 90(6):E122-3. PMID: 25703132.
    Citations: 1     Fields:    Translation:Humans
  130. Reagan JL, Sullivan MR, Winer ES, Lansigan F, Cardin MS, Castillo JJ. Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. Leuk Res. 2015 Aug; 39(8):812-7. PMID: 26045177.
    Citations: 1     Fields:    Translation:Humans
  131. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 09; 372(15):1430-40. PMID: 25853747.
    Citations: 110     Fields:    Translation:HumansCTClinical Trials
  132. Castillo JJ, Olszewski AJ, Hunter ZR, Kanan S, Meid K, Treon SP. Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database. Cancer. 2015 Jul 01; 121(13):2230-6. PMID: 25757851.
    Citations: 3     Fields:    Translation:Humans
  133. Garg M, Lee BE, McGarry K, Mangray S, Castillo JJ. CD20-negative diffuse large B-cell lymphoma presenting with lactic acidosis. Am J Hematol. 2015 Mar; 90(3):E49-50. PMID: 25417998.
    Citations: 1     Fields:    Translation:HumansCells
  134. Castillo JJ, Chavez JC, Hernandez-Ilizaliturri FJ, Montes-Moreno S. CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options. Expert Rev Hematol. 2015 Jun; 8(3):343-54. PMID: 25641215.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  135. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015 Apr 09; 125(15):2323-30. PMID: 25636338.
    Citations: 34     Fields:    Translation:HumansAnimalsCells
  136. Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015 May; 169(3):352-5. PMID: 25612847.
    Citations: 12     Fields:    Translation:Humans
  137. Olszewski AJ, Shrestha R, Castillo JJ. Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base. J Clin Oncol. 2015 Feb 20; 33(6):625-33. PMID: 25584010.
    Citations: 10     Fields:    Translation:Humans
  138. Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015 Jul; 170(1):134-8. PMID: 25582069.
    Citations: 19     Fields:    Translation:Humans
  139. Castillo JJ, Ghobrial IM, Treon SP. Biology, prognosis, and therapy of Waldenström Macroglobulinemia. Cancer Treat Res. 2015; 165:177-95. PMID: 25655610.
    Citations: 3     Fields:    Translation:Humans
  140. Jurczyszyn A, Czepiel J, Gdula-Argasinska J, Pasko P, Czapkiewicz A, Librowski T, Perucki W, Butrym A, Castillo JJ, Skotnicki AB. Plasma fatty acid profile in multiple myeloma patients. Leuk Res. 2015 Apr; 39(4):400-5. PMID: 25666255.
    Citations: 6     Fields:    Translation:Humans
  141. Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr; 169(1):81-9. PMID: 25521528.
    Citations: 11     Fields:    Translation:Humans
  142. Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015 Feb; 90(2):100-4. PMID: 25349134.
    Citations: 4     Fields:    Translation:HumansCells
  143. Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol. 2015 Mar; 168(5):701-7. PMID: 25371371.
    Citations: 8     Fields:    Translation:HumansCells
  144. Beltrán BE, Castillo JJ, Quiñones P, Morales D, Paredes A, Nieto G, Miranda RN, Torres-Cabala CA. Extranodal marginal zone lymphoma from ocular adnexae with subcutaneous involvement. Am J Dermatopathol. 2014 Nov; 36(11):e189-93. PMID: 25238445.
    Citations:    Fields:    Translation:Humans
  145. Bibas M, Castillo JJ. Current knowledge on HIV-associated Plasmablastic Lymphoma. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014064. PMID: 25408850.
    Citations: 12     
  146. Beltrán BE, Maza I, Moisés-Alfaro CB, Vasquez L, Quiñones P, Morales D, Sánchez G, Paredes G, Oscanoa M, Gerónimo J, Miranda RN, Castillo JJ. Thalidomide for the treatment of hydroa vacciniforme-like lymphoma: report of four pediatric cases from Peru. Am J Hematol. 2014 Dec; 89(12):1160-1. PMID: 25196949.
    Citations: 1     Fields:    Translation:Humans
  147. Castillo JJ, Bower M, Brühlmann J, Novak U, Furrer H, Tanaka PY, Besson C, Montoto S, Cwynarski K, Abramson JS, Dalia S, Bibas M, Connors JM, Furman M, Nguyen ML, Cooley TP, Beltran BE, Collins JA, Vose JM, Xicoy B, Ribera JM. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study. Cancer. 2015 Feb 01; 121(3):423-31. PMID: 25251326.
    Citations: 7     Fields:    Translation:Humans
  148. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014 Nov; 25(11):2211-2217. PMID: 25193992.
    Citations: 19     Fields:    Translation:Humans
  149. Aguilar C, Beltran B, Quiñones P, Carbajal T, Vilcapaza J, Yabar A, Segura P, Quintanilla-Martinez L, Miranda RN, Castillo JJ. Large B-cell lymphoma arising in cardiac myxoma or intracardiac fibrinous mass: a localized lymphoma usually associated with Epstein-Barr virus? Cardiovasc Pathol. 2015 Jan-Feb; 24(1):60-4. PMID: 25307939.
    Citations: 4     Fields:    Translation:Humans
  150. Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens AM, Shah N, Fenske TS, Zelenetz AD, Landsburg DJ, Howlett C, Mato A, Jaglal M, Chavez JC, Tsai JP, Reddy N, Li S, Handler C, Flowers CR, Cohen JB, Blum KA, Song K, Sun HL, Press O, Cassaday R, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014 Oct 09; 124(15):2354-61. PMID: 25161267.
    Citations: 48     Fields:    Translation:Humans
  151. Jurczyszyn A, Czepiel J, Gdula-Argasinska J, Czapkiewicz A, Biesiada G, Drózdz M, Perucki W, Castillo JJ. Erythrocyte membrane fatty acids in multiple myeloma patients. Leuk Res. 2014 Oct; 38(10):1260-5. PMID: 25192858.
    Citations: 2     Fields:    Translation:HumansCells
  152. Treon SP, Hunter ZR, Castillo JJ, Merlini G. Waldenström macroglobulinemia. Hematol Oncol Clin North Am. 2014 Oct; 28(5):945-70. PMID: 25212891.
    Citations: 4     Fields:    Translation:HumansCells
  153. Apor E, O'Brien J, Stephen M, Castillo JJ. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Leuk Res. 2014 Sep; 38(9):1067-71. PMID: 25052307.
    Citations: 1     Fields:    Translation:Humans
  154. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014 Jun 19; 123(25):3999-4000. PMID: 24948623.
    Citations: 10     Fields:    Translation:Humans
  155. Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1877-84. PMID: 24946718.
    Citations: 7     Fields:    Translation:Humans
  156. Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Patterson CJ, Tsakmaklis N, Kanan S, Rodig S, Castillo JJ, Treon SP. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia. 2015 Jan; 29(1):169-76. PMID: 24912431.
    Citations: 24     Fields:    Translation:HumansCells
  157. Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014 Jul 24; 124(4):503-10. PMID: 24859363.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  158. Fircanis S, Merriam P, Khan N, Castillo JJ. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014 Aug; 89(8):E125-32. PMID: 24753145.
    Citations: 11     Fields:    Translation:Humans
  159. Olszewski AJ, Winer ES, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014 Aug; 38(8):866-73. PMID: 24837081.
    Citations: 4     Fields:    Translation:Humans
  160. Reagan JL, Castillo JJ. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol. 2014 May; 10(7):1147-55. PMID: 24947256.
    Citations: 2     Fields:    Translation:HumansAnimals
  161. Gavini A, Reagan JL, Winer ES, Castillo JJ. Primary refractory Hodgkin lymphoma: limited options and poor survival--but not always. Am J Hematol. 2014 Aug; 89(8):853-7. PMID: 24382755.
    Citations:    Fields:    Translation:Humans
  162. Castillo JJ, Iyengar M, Kuritzky B, Bishop KD. Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies. Onco Targets Ther. 2014; 7:333-42. PMID: 24591840.
    Citations: 4     
  163. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014 Mar; 89(3):310-4. PMID: 24273125.
    Citations: 11     Fields:    Translation:Humans
  164. Castillo JJ, Reagan JL, Bishop KD, Apor E. Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies. Br J Haematol. 2014 May; 165(3):300-15. PMID: 24533596.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  165. Xu L, Hunter ZR, Yang G, Cao Y, Liu X, Manning R, Tripsas C, Chen J, Patterson CJ, Kluk M, Kanan S, Castillo J, Lindeman N, Treon SP. Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Leukemia. 2014 Aug; 28(8):1698-704. PMID: 24509637.
    Citations: 17     Fields:    Translation:Humans
  166. Castillo JJ, Nadeem O. Improving the accuracy in prognosis for Burkitt lymphoma patients. Expert Rev Anticancer Ther. 2014 Feb; 14(2):125-7. PMID: 24329420.
    Citations:    Fields:    Translation:Humans
  167. Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, Shifrin DA, O'Malley DP, Cheah CY, Bacchi CE, Gualco G, Li S, Keech JA, Hochberg EP, Carty MJ, Hanson SE, Mustafa E, Sanchez S, Manning JT, Xu-Monette ZY, Miranda AR, Fox P, Bassett RL, Castillo JJ, Beltran BE, de Boer JP, Chakhachiro Z, Ye D, Clark D, Young KH, Medeiros LJ. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014 Jan 10; 32(2):114-20. PMID: 24323027.
    Citations: 36     Fields:    Translation:Humans
  168. Castillo JJ, Ingham RR, Reagan JL, Furman M, Dalia S, Mitri J. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta-analysis of observational studies. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):122-30. PMID: 24360912.
    Citations: 4     Fields:    Translation:Humans
  169. Pham A, Reagan JL, Castillo JJ. Multiple myeloma-induced hyperammonemic encephalopathy: an entity associated with high in-patient mortality. Leuk Res. 2013 Oct; 37(10):1229-32. PMID: 23932549.
    Citations: 3     Fields:    Translation:Humans
  170. Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Oct 15; 119(20):3672-9. PMID: 23913575.
    Citations: 6     Fields:    Translation:Humans
  171. Dalia S, Chavez J, Castillo JJ, Sokol L. Hepatitis B infection increases the risk of non-Hodgkin lymphoma: a meta-analysis of observational studies. Leuk Res. 2013 Sep; 37(9):1107-15. PMID: 23809055.
    Citations: 17     Fields:    Translation:HumansCells
  172. Beltran BE, Quiñones P, Morales D, Alva JC, Miranda RN, Lu G, Shah BD, Sotomayor EM, Castillo JJ. Follicular lymphoma with leukemic phase at diagnosis: a series of seven cases and review of the literature. Leuk Res. 2013 Sep; 37(9):1116-9. PMID: 23790442.
    Citations: 1     Fields:    Translation:Humans
  173. Reagan JL, Fast LD, Safran H, Nevola M, Winer ES, Castillo JJ, Butera JN, Quesenberry MI, Young CT, Quesenberry PJ. Cellular immunotherapy for refractory hematological malignancies. J Transl Med. 2013 Jun 19; 11:150. PMID: 23782682.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  174. Castillo J. Reply to a. Messori et al. Am J Hematol. 2013 May; 88(5):435-6. PMID: 23420513.
    Citations:    Fields:    Translation:Humans
  175. Beltrán BE, Kuritzky B, Quiñones P, Morales D, Alva JC, Lu G, Goswami M, Miranda RN, Castillo JJ. Extranodal marginal zone lymphoma of the cranial dura mater: report of three cases and systematic review of the literature. Leuk Lymphoma. 2013 Oct; 54(10):2306-9. PMID: 23363270.
    Citations: 1     Fields:    Translation:HumansCells
  176. Castillo JJ, Sinclair N, Beltrán BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN. Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2013 Apr; 37(4):386-91. PMID: 23352640.
    Citations: 1     Fields:    Translation:Humans
  177. Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Ann Oncol. 2013 May; 24(5):1352-9. PMID: 23348804.
    Citations: 4     Fields:    Translation:Humans
  178. Nakhla PS, Butera JN, Treaba DO, Castillo JJ, Quesenberry PJ. Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. Leuk Lymphoma. 2013 Aug; 54(8):1647-51. PMID: 23185961.
    Citations: 3     Fields:    Translation:HumansCells
  179. Mega AE, Castillo JJ, Fenton MA, Bartley C, Kaplan A, Murphy B, Iannuccilli J, Stobie L, Touloumtzis C, Schumacher A, Korber S, Faricy-Anderson KE, Bakalarski P, Sikov WM, Safran H, Thomas AG, Isdale D, Rosati K. Assessment of the effectiveness of a prechemotherapy teaching session: A Brown University Oncology Group study. J Clin Oncol. 2012 Dec; 30(34_suppl):260. PMID: 28147077.
    Citations:    
  180. Fircanis S, Shields R, Castillo J, Mega A, Schiffman F. The girl with the iron tattoo. Virulence. 2012 Nov 15; 3(7):599-600. PMID: 23076330.
    Citations:    Fields:    Translation:HumansCells
  181. Castillo JJ, Beltran BE. Not all aggressive adult T-cell leukemia/lymphoma subtypes are created equal. J Clin Oncol. 2012 Oct 01; 30(28):3560; author reply 3561. PMID: 22927519.
    Citations:    Fields:    Translation:Humans
  182. Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Feb 01; 119(3):629-38. PMID: 22893605.
    Citations: 20     Fields:    Translation:Humans
  183. Treaba DO, Khedr S, Mangray S, Jackson C, Castillo JJ, Winer ES. Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature. Case Rep Hematol. 2012; 2012:875039. PMID: 22953080.
    Citations:    
  184. Castillo JJ, Shum H, Lahijani M, Winer ES, Butera JN. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012 Dec; 53(12):2378-82. PMID: 22591071.
    Citations: 11     Fields:    Translation:HumansCells
  185. Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012; 17(6):756-65. PMID: 22618570.
    Citations: 35     Fields:    Translation:Humans
  186. Castillo JJ, Dhami PK, Curry S, Brennan K. No association between cigarette smoking and incidence of plasma cell myeloma: a meta-analysis of 17 observational studies. Am J Hematol. 2012 Jul; 87(7):729-31. PMID: 22566293.
    Citations: 4     Fields:    Translation:Humans
  187. Castillo JJ, Dalia S. Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies. Leuk Lymphoma. 2012 Oct; 53(10):1911-9. PMID: 22397720.
    Citations: 4     Fields:    Translation:Humans
  188. Castillo JJ, Furman M, Beltrán BE, Bibas M, Bower M, Chen W, Díez-Martín JL, Liu JJ, Miranda RN, Montoto S, Nanaji NM, Navarro JT, Seegmiller AC, Vose JM. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012 Nov 01; 118(21):5270-7. PMID: 22510767.
    Citations: 23     Fields:    Translation:Humans
  189. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood. 2012 May 24; 119(21):4845-50. PMID: 22496152.
    Citations: 33     Fields:    Translation:Humans
  190. Reagan JL, Castillo JJ. Why is my patient neutropenic? Hematol Oncol Clin North Am. 2012 Apr; 26(2):253-66, vii. PMID: 22463826.
    Citations: 1     Fields:    Translation:Humans
  191. Beltran BE, Morales D, Quinones P, Miranda RN, Goswami M, Castillo JJ. Peripheral T-cell lymphoma with a regulatory T-cell phenotype: report of a nodal and an extranodal case from Peru. Appl Immunohistochem Mol Morphol. 2012 Mar; 20(2):196-200. PMID: 21836498.
    Citations: 1     Fields:    Translation:HumansCells
  192. Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol. 2012 Mar; 87(3):330-3. PMID: 22308010.
    Citations: 4     Fields:    Translation:Humans
  193. Winer ES, Ingham RR, Castillo JJ. PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Mar; 21(3):355-61. PMID: 22300471.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  194. Bishop KD, Castillo JJ. Risk factors associated with Clostridium difficile infection in adult oncology patients with a history of recent hospitalization for febrile neutropenia. Leuk Lymphoma. 2012 Aug; 53(8):1617-9. PMID: 22221036.
    Citations: 4     Fields:    Translation:HumansCells
  195. Castillo JJ, Reagan JL, Ingham RR, Furman M, Dalia S, Merhi B, Nemr S, Zarrabi A, Mitri J. Obesity but not overweight increases the incidence and mortality of leukemia in adults: a meta-analysis of prospective cohort studies. Leuk Res. 2012 Jul; 36(7):868-75. PMID: 22285508.
    Citations: 15     Fields:    Translation:Humans
  196. Castillo JJ, Beltran BE, Song MK, Ilic I, Leppa S, Nurmi H, Seki R, Uccella S, Li JM, Treaba DO, Stachurski D, Butera JN. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012 Apr; 36(4):413-7. PMID: 22277681.
    Citations: 13     Fields:    Translation:Humans
  197. Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012 Jan; 21(1):15-22. PMID: 22112004.
    Citations: 23     Fields:    Translation:Humans
  198. Beltran BE, Quiñones P, Morales D, Revilla JC, Alva JC, Castillo JJ. Diffuse large B-cell lymphoma in human T-lymphotropic virus type 1 carriers. Leuk Res Treatment. 2012; 2012:262363. PMID: 23198156.
    Citations: 2     
  199. Castillo JJ, Dalia S, Shum H. Meta-analysis of the association between cigarette smoking and incidence of Hodgkin's Lymphoma. J Clin Oncol. 2011 Oct 10; 29(29):3900-6. PMID: 21911724.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  200. Beltran BE, Morales D, Quiñones P, Medeiros LJ, Miranda RN, Castillo JJ. EBV-positive diffuse large b-cell lymphoma in young immunocompetent individuals. Clin Lymphoma Myeloma Leuk. 2011 Dec; 11(6):512-6. PMID: 21889434.
    Citations: 14     Fields:    Translation:Humans
  201. Beltran BE, Castillo JJ, Morales D, de Mendoza FH, Quinones P, Miranda RN, Gallo A, Lopez-Ilasaca M, Butera JN, Sotomayor EM. EBV-positive diffuse large B-cell lymphoma of the elderly: a case series from Peru. Am J Hematol. 2011 Aug; 86(8):663-7. PMID: 21761432.
    Citations: 10     Fields:    Translation:HumansCells
  202. Castillo JJ. Plasmablastic lymphoma: are more intensive regimens needed? Leuk Res. 2011 Dec; 35(12):1547-8. PMID: 21788074.
    Citations: 6     Fields:    Translation:Humans
  203. Castillo JJ, Sinclair N, Stachurski D, Jacobsen ED. Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: a unifying diagnosis. Am J Hematol. 2011 Aug; 86(8):690-3. PMID: 21630306.
    Citations:    Fields:    Translation:HumansCells
  204. Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, Colvin GA, Butera JN. HIV-negative plasmablastic lymphoma: not in the mouth. Clin Lymphoma Myeloma Leuk. 2011 Apr; 11(2):185-9. PMID: 21575922.
    Citations: 16     Fields:    Translation:Humans
  205. Castillo JJ, Reagan JL. Plasmablastic lymphoma: a systematic review. ScientificWorldJournal. 2011 Mar 22; 11:687-96. PMID: 21442146.
    Citations: 31     Fields:    Translation:Humans
  206. Castillo JJ, Beltran BE, Bibas M, Bower M, Collins JA, Cwynarski K, Diez-Martin JL, Hernandez-Ilizaliturri F, Horwitz SM, Montoto S, Pantanowitz L, Ribera JM, Vose JM. Prognostic factors in patients with HIV-associated peripheral T-cell lymphoma: a multicenter study. Am J Hematol. 2011 Mar; 86(3):256-61. PMID: 21328430.